Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation, Restricted Stock and Stock Options: (Tables)

v3.21.2
Stock-Based Compensation, Restricted Stock and Stock Options: (Tables)
6 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of stock based compensation expenses
    Three months ended
September 30,
    Six months ended
September 30,
 
    2021     2020     2021     2020  
    (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)  
Research and development expenses   $ 113     $ 141     $ 145     $ 1,293  
Selling, general and administrative expenses     2,988       830       5,539       7,757  
Total stock-based compensation   $ 3,101     $ 971     $ 5,684     $ 9,050  

 

Schedule of restricted stock awards
    Number of
Shares
    Weighted
Average
Grant-Date
Fair Value
 
Unvested at March 31, 2021     1,061,905     $ 4.50  
Granted     1,200,000     $ 4.74  
Vested     (222,222 )   $ 4.78  
Unvested at September 30, 2021 (unaudited)     2,039,683     $ 4.61  

 

    Number of Shares     Weighted Average Grant-Date  Fair Value  
Unvested at March 31, 2021     777,778     $ 5.12  
Vested     (66,666 )   $ 5.12  
Canceled     (711,112 )   $ 5.12  
Unvested at September 30, 2021 (unaudited)    
-
    $ 5.12  

Schedule of stock options granted
    Three Months Ended
September 30,
    Six Months Ended
September 30,
 
    2021     2020     2021     2020  
Dividend yield     0%     0%       0%       0%  
Expected price volatility     50%       50%       50%       50%  
Risk free interest rate     0.66%-1.30%       0.16% - 0.44%       0.35%-1.30%       0.16% - 0.44%  
Expected term      5-7 years        5-6 years        3-7 years        5-6 years  

 

Schedule of stock options activity
    Shares
Underlying
Options
    Weighted
Average
Exercise
Price
    Weighted
Average Remaining
Contractual
Term
(Years)
    Aggregate
Intrinsic
Value
 
Outstanding at March 31, 2019     1,937,833     $ 0.54       9.2     $ 3,720,395  
Outstanding at March 31, 2020     1,937,833     $ 0.54       8.2     $ 4,243,610  
Granted     8,949,107     $ 3.23       8.4      
 
 
Exercised     (25,000 )   $ 0.15      
-
     
 
 
Outstanding at March 31, 2021     10,928,607 *   $ 2.73       8.2     $ 17,524  
Granted     1,227,204     $ 3.49       9.8      
 
 
Exercised     (419,000 )   $ 0.51      
-
     
 
 
Canceled     (816,379 )   $ 3.88      
-
     
 
 
Outstanding at September 30, 2021 (unaudited)     10,920,432     $ 2.83       7.8     $ 13,089  
                                 
Exercisable at September 30, 2021 (unaudited)     9,756,406     $ 2.73       7.7     $ 12,483  

 

Schedule of warrant activity
    Shares
Underlying
Warrants
    Weighted
Average
Exercise
Price
    Weighted
Average Remaining
Contractual
Term
(Years)
    Aggregate
Intrinsic
Value
 
Outstanding at March 31, 2021     3,883,083     $ 2.49       4.6     $ 7,763  
Issued     550,724     $ 4.07       5.0      
 
 
Canceled     (133,630 )   $ 5.63      
-
     
 
 
Outstanding at September 30, 2021 (unaudited)     4,300,177     $ 2.60       4.2     $ 7,026  
                                 
Exercisable at September 30, 2021 (unaudited)     3,368,422     $ 1.91       4.1     $ 6,447  

Schedule of estimated the fair value of the warrants
    Three Months Ended September 30,     Six Months Ended September 30,  
    2021     2021  
Dividend yield     0%     0%  
Expected price volatility     50%     50%  
Risk free interest rate     0.66%-1.30%     0.35%-1.30%  
Expected term      5-7 years        3-7 years